Data on the use of convalescent plasma in the treatment of covid-19 are scarce: the results of randomized studies involving mainly immunocompetent patients are disappointing, while case series or retrospective data on more selected patients , in particular immunocompromised patients suggest a benefit in these patients whose clinical manifestation seems essentially related to the uncontrolled infection and not the cytokine storm.

Inclusion criteria:

• Adult patient
• Immunocompromised patient (solid neoplasia, malignant hemopathy, solid organ transplantation, primary immune deficiency, systemic disease, chronic inflammatory disease, etc.)
• Hospitalized between 25/02/2020 and 15/01/2023 at HUS, ICANS, CH Colmar and CH Mulhouse
• Having received curative monoclonal antibody treatment or convalescent plasma treatment for SARS-Cov2 infection
• Patient who has not expressed, after being informed, his opposition to the reuse of his data for scientific research purposes.

Exclusion criteria:

• Subject who expressed their opposition to participating in the study
• Subject under guardianship, curatorship or safeguard of justice

Adult patient immunocompromised patient hospitalized between 25/02/2020 and 15/01/2023